JP2019501141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501141A5 JP2019501141A5 JP2018527804A JP2018527804A JP2019501141A5 JP 2019501141 A5 JP2019501141 A5 JP 2019501141A5 JP 2018527804 A JP2018527804 A JP 2018527804A JP 2018527804 A JP2018527804 A JP 2018527804A JP 2019501141 A5 JP2019501141 A5 JP 2019501141A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- peptide
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259178P | 2015-11-24 | 2015-11-24 | |
| US62/259,178 | 2015-11-24 | ||
| PCT/CA2016/051379 WO2017088058A1 (en) | 2015-11-24 | 2016-11-24 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135993A Division JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501141A JP2019501141A (ja) | 2019-01-17 |
| JP2019501141A5 true JP2019501141A5 (https=) | 2019-12-26 |
| JP6810146B2 JP6810146B2 (ja) | 2021-01-06 |
Family
ID=58762819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527804A Active JP6810146B2 (ja) | 2015-11-24 | 2016-11-24 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| JP2020135993A Active JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135993A Active JP7095035B2 (ja) | 2015-11-24 | 2020-08-11 | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11034727B2 (https=) |
| EP (2) | EP3925969B1 (https=) |
| JP (2) | JP6810146B2 (https=) |
| CN (2) | CN108473541B (https=) |
| AU (2) | AU2016358324B2 (https=) |
| CA (2) | CA3006313C (https=) |
| DK (1) | DK3380495T3 (https=) |
| ES (2) | ES2882634T3 (https=) |
| PL (1) | PL3380495T3 (https=) |
| PT (1) | PT3380495T (https=) |
| SI (1) | SI3380495T1 (https=) |
| WO (1) | WO2017088058A1 (https=) |
| ZA (1) | ZA201804117B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3380495T1 (sl) * | 2015-11-24 | 2022-01-31 | Transfert Plus, S.E.C. | Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDIC COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| US11389460B2 (en) | 2017-09-15 | 2022-07-19 | City Of Hope | Methods and compositions for treating endometrial cancer |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| CA3110414A1 (en) * | 2018-08-24 | 2020-02-27 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
| EP3986921A2 (en) * | 2019-06-20 | 2022-04-27 | Aarhus Universitet | Sorcs2 crystal structure and uses thereof |
| IL293553A (en) * | 2019-12-06 | 2022-08-01 | Theratechnologies Inc | Conjugated compounds that bind sortilin, preparations and uses thereof for the treatment of cancer |
| US20230338555A1 (en) * | 2020-05-18 | 2023-10-26 | Ionis Pharmaceuticals, Inc. | Conjugated oligonucleotides and uses thereof |
| WO2022178634A1 (en) * | 2021-02-26 | 2022-09-01 | Transfert Plus, Société En Commandite | Methods and sortilin binding conjugate compounds for targeting cancer stem cells |
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| CN117904303B (zh) * | 2024-03-18 | 2024-06-18 | 湖南宏雅基因技术有限公司 | Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用 |
| CN118384289A (zh) * | 2024-04-24 | 2024-07-26 | 青岛科技大学 | 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用 |
| WO2025236098A1 (en) * | 2024-05-16 | 2025-11-20 | Theratechnologies Inc. | Peptide conjugates of maytansinoids and uses thereof |
| WO2026021513A1 (zh) * | 2024-07-25 | 2026-01-29 | 上海湃鸿生物科技有限公司 | 一种多肽药物偶联物及其制备方法和应用 |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US8344211B2 (en) | 2008-08-13 | 2013-01-01 | Ceres, Inc. | Plant nucleotide sequences and corresponding polypeptides |
| TW200634019A (en) | 2004-12-21 | 2006-10-01 | Wyeth Corp | Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors |
| US8486635B2 (en) * | 2006-05-30 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| EP2077278A1 (fr) * | 2007-12-21 | 2009-07-08 | Centre National de la Recherche Scientifique (CNRS) | Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques |
| KR101614558B1 (ko) * | 2008-04-27 | 2016-04-22 | 하. 룬드벡 아크티에셀스카브 | 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도 |
| US20120039865A1 (en) * | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8147849B2 (en) | 2009-02-20 | 2012-04-03 | Novartis Ag | Protective antigens for group B Streptococcus hypervirulent strains |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| WO2011082290A2 (en) | 2009-12-31 | 2011-07-07 | Organomed Corporation | Formulations from natural products, turmeric, and aspirin |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| SI3280441T1 (sl) | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| SI3380495T1 (sl) * | 2015-11-24 | 2022-01-31 | Transfert Plus, S.E.C. | Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDIC COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| CA3110414A1 (en) * | 2018-08-24 | 2020-02-27 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
-
2016
- 2016-11-24 SI SI201631303T patent/SI3380495T1/sl unknown
- 2016-11-24 WO PCT/CA2016/051379 patent/WO2017088058A1/en not_active Ceased
- 2016-11-24 CA CA3006313A patent/CA3006313C/en active Active
- 2016-11-24 CN CN201680078822.9A patent/CN108473541B/zh active Active
- 2016-11-24 ES ES16867488T patent/ES2882634T3/es active Active
- 2016-11-24 EP EP21174271.3A patent/EP3925969B1/en active Active
- 2016-11-24 US US15/778,626 patent/US11034727B2/en active Active
- 2016-11-24 CA CA3071494A patent/CA3071494C/en active Active
- 2016-11-24 ES ES21174271T patent/ES3053967T3/es active Active
- 2016-11-24 AU AU2016358324A patent/AU2016358324B2/en active Active
- 2016-11-24 PT PT168674885T patent/PT3380495T/pt unknown
- 2016-11-24 JP JP2018527804A patent/JP6810146B2/ja active Active
- 2016-11-24 PL PL16867488T patent/PL3380495T3/pl unknown
- 2016-11-24 EP EP16867488.5A patent/EP3380495B1/en active Active
- 2016-11-24 CN CN202310436312.6A patent/CN116478245A/zh active Pending
- 2016-11-24 DK DK16867488.5T patent/DK3380495T3/da active
-
2018
- 2018-06-20 ZA ZA2018/04117A patent/ZA201804117B/en unknown
-
2020
- 2020-08-11 JP JP2020135993A patent/JP7095035B2/ja active Active
-
2021
- 2021-02-19 AU AU2021201085A patent/AU2021201085B2/en active Active
- 2021-04-23 US US17/239,544 patent/US11780882B2/en active Active
-
2023
- 2023-08-30 US US18/240,295 patent/US12269902B2/en active Active
-
2025
- 2025-03-11 US US19/076,662 patent/US20250296957A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501141A5 (https=) | ||
| JP2021535209A5 (https=) | ||
| JP2021502810A5 (https=) | ||
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| JP2010510801A5 (https=) | ||
| JP2013506411A5 (https=) | ||
| TN2012000145A1 (en) | Bispecific binding molecules for anti-angiogenesis therapy | |
| JP2017528117A5 (https=) | ||
| PH12018500520A1 (en) | Cd3 binding polypeptides | |
| JP2020506727A5 (https=) | ||
| JP2009521206A5 (https=) | ||
| JP2008529539A5 (https=) | ||
| JP2010531140A5 (https=) | ||
| JP2016187356A5 (https=) | ||
| JP2019513764A5 (https=) | ||
| HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
| RU2018131636A (ru) | Новые конъюгаты аманитина | |
| JP2017513478A5 (https=) | ||
| JP2016516061A5 (https=) | ||
| JP2013121977A5 (https=) | ||
| JP2017506217A5 (https=) | ||
| JP2019501141A (ja) | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート | |
| JP2013527761A5 (https=) | ||
| JP2017513826A5 (https=) | ||
| JP2011526891A5 (https=) |